Instruction for use: Euphyllin solution for injections 24%

Dosage form: Solution for intravenous administration

Active substance: Aminophyllinum

ATX

R03DA05 Aminophylline

Pharmacological group

Adenosinergic agents

The nosological classification (ICD-10)

G45 Transient transient cerebral ischemic attacks [attacks] and related syndromes: Ischemic neurological disorders; Acute cerebrovascular insufficiency; Repeated transient cerebral ischemia; Transient ischemic attack; Transient ischemic condition; Transient ischemic attack; Transient ischemic attack; transient ischemia; Transient cerebral ischemic attack; Transient cerebral ischemia; Transient ischemic attacks; Chronic cerebral ischemia; Drop attacks; Transient ischemic attacks; Transient ischemic cerebrovascular accident; Ischemic brain damage; Subclavian steal syndrome

G93.6 Brain edema: Intraoperative edema of the brain; Cerebral edema; Post-traumatic swelling of the brain; Brain edema associated with radiation therapy; Brain edema associated with head trauma; Post-traumatic cerebral edema; Edema of the brain in poisoning

I27 Other forms of cardiopulmonary diseases: Chronic pulmonary heart disease; Hypertension pulmonary circulation; Pulmonary hypertension; Pulmonary heart disease; pulmonary heart disease; Cardio-pulmonary insufficiency; Secondary pulmonary hypertension; Chronic pulmonary heart; Eisenmenger syndrome

I50.1 Left ventricular failure: Cardiac asthma; Asymptomatic dysfunction of the left ventricle; Asymptomatic left ventricular heart failure; Diastolic dysfunction of the left ventricle; Left ventricular dysfunction; Changes in the left ventricle with myocardial infarction; Left ventricular heart failure; Violation of the function of the left ventricle; Acute left ventricular failure; Acute cardiac left ventricular failure; Cardiac asthma; Heart failure of left ventricular; Changes in the lungs with left ventricular failure; Precordial abnormal pulsation; Lack of left ventricle

I99 Other and unspecified disorders of the circulatory system: angiopathy; Arterial angiopathy; Atherosclerotic angiopathy; Hemodynamic right heart defects; Hemodynamic defect of the right heart; coronary angiopathy; Infringement of blood circulation; Violation of circulation; Violation microcirculation in organs and tissues; Peripheral circulatory disorders; Disorders of the peripheral circulation in the extremities; circulatory failure; Hemodynamic instability occlusion of arteriovenous origin; Acute circulatory failure; Psevdostenokardicheskie state; Psevdostenokardicheskoe disorder; circulatory disorder; Cardiovascular diseases; Vascular insufficiency; Thrombosis arteriovenous shunt; Thrombosis with prosthetic heart valves; Deterioration of blood circulation in the pelvic organs; Functional failure of the cardiovascular system; Functional disorders of the cardiovascular system; Chronic arterial insufficiency; Chronic heart failure; Age-related vascular disease; The risk of thrombosis

J45 Asthma: Asthma of physical effort; Asthmatic conditions; Bronchial asthma; Bronchial asthma of light course; Bronchial asthma with difficulty in sputum discharge; Bronchial asthma of severe course; Bronchial asthma physical effort; Hypersecretory asthma; The hormone-dependent form of bronchial asthma; Curbing asthma attacks with bronchial asthma; Non-allergic bronchial asthma; Night Asthma; Exacerbation of bronchial asthma; Attack of bronchial asthma; Endogenous forms of asthma; Night attacks of asthma; Cough with bronchial asthma

J98.8.0 * Bronchospasm: Bronchospasm with bronchial asthma; Bronchospasm when exposed to an allergen; Bronchospastic reactions; Bronchospastic conditions; Bronchospastic syndrome; Diseases accompanied by bronchospastic syndrome; Reversible bronchospasm; Spasmodic cough

N28.9 Kidney and ureter's disease, unspecified: Disturbance of ureter function; Autoimmune kidney damage; Kidney Diseases; Infringement of a renal blood flow; Impaired renal function; Impaired renal function; Nondiabetic nephropathy; Insufficiency of excretory function of the kidneys; Nephrogenic osteopathy; Nephropathic syndrome; Nephropathy of minimal changes; Maintaining kidney function; Chronic kidney disease; Megaloureter

Composition and release form

1 tablet contains aminophylline 0.15 g; In a glass jar 30 pcs. Or in a blister 10 pcs., In a pencil case 1 or 3 blisters.

1 ml solution for injection - 0.024 or 0.12 g; In ampoules.

Pharmachologic effect

Mode action - bronchodilating, diuretic, spasmolytic, vasodilating.

It blocks adenosine receptors, inhibits phosphodiesterase (with accumulation of cAMP) and reduces the concentration of free calcium in smooth muscles.

Indication for the Euphyllin solution for injections 24%

Bronchial asthma, bronchospastic syndrome, pulmonary hypertension, cardiac asthma; Chronic cerebral circulatory insufficiency, cerebral edema, impaired renal blood flow.

Contraindications

Myocardial infarction, pronounced coronary spasm, paroxysmal tachycardia, coronaro atherosclerosis.

Side effects

Dyspeptic disorders (nausea, vomiting, etc.), headache, dizziness, hypotension, palpitations, convulsions.

Interaction

Compatible with other antispasmodics.

Dosing and Administration

Inside, after eating - 0.1-0.2 g 2-3 times a day; Children - 7-10 mg / kg per day in 4 divided doses. Duration of treatment - up to several months.

Storage conditions of the drug Euphyllin solution for injections 24%

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Euphyllin solution for injections 24%

Solution for intravenous administration 2.4% - 3 years.

Solution for intramuscular injection 24% - 2 years.

Tablets 0.15 g - 5 years.

Do not use after the expiry date printed on the package.